Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$45.11 USD
+1.56 (3.58%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $45.10 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RARE 45.11 +1.56(3.58%)
Will RARE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics
Other News for RARE
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)
First Week of RARE June 21st Options Trading
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical